

Press Release

Zug, 6 October 2011

Request to call an Extraordinary Shareholders Meeting of Basilea

On 4 October 2011 HBM Bioventures sent a letter to the Board of Directors of Basilea Pharmaceutica Ltd. requesting the convening of an extraordinary shareholders meeting, aimed at strengthening Basilea's Board of Directors. The meeting is to take place no later than 30 November 2011. HBM Bioventures has put forward three independent candidates for the Board of Directors: Dr Thomas Werner, Dr Seng Chin Mah and Dr Thomas M. Rinderknecht. A fourth candidate will be proposed in close accord with Basilea. The original letter can be accessed at the following address www.hmbioventures.com.

As at 30 September 2011 HBM BioVentures held 1,726,379 registered shares or 18% of the outstanding voting rights of Basilea Pharmaceutica Ltd, making it its largest shareholder.

For further information, please contact Dr Andreas Wicki, CEO HBM BioVentures Ltd, Tel.: +41 41 768 11 08, andreas.wicki@hmbioventures.com

About HBM BioVentures Ltd

HBM BioVentures pursues successful investments in the healthcare sector. The Company holds and manages an international portfolio of some twenty five promising companies. Many of these companies have their lead products already available on the market, or at an advanced stage of development. The focus of investment is on follow-on financing for existing portfolio companies. These portfolio companies are closely tracked and actively guided on their strategic directions. This is what makes HBM BioVentures an interesting alternative to investing in big pharma and biotech companies. HBM BioVentures has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

Disclaimer

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act

NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA



(Wertpapierprospektgesetz). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM BioVentures Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.

HBM BioVentures AG
Bundesplatz 1
CH-6300 Zug/ Switzerland
Tel:+41 41 768 11 08
Fax:+41 41 768 11 09
info@hbmbioventures.com
www.hbmbioventures.com